The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Open accessAbstract
BACKGROUND: alteration. Data are needed to confirm and expand on the findings of the phase 2 study. METHODS: alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). We randomly assigned the patients in a 2:1 ratio to receive oral rucaparib (600 mg twice daily) or a physician's choice control (docetaxel or a second-generation ARPI [abiraterone acetate or enzalutamide]). The primary outcome was the median duration of imaging-based progression-free survival according to independent review. RESULTS: alteration. At 62 months, the duration of imaging-based progression-free survival was significantly longer in the rucaparib group than in the control group, both in the BRCA subgroup (median, 11.2 months and 6.4 months, respectively; hazard ratio, 0.50; 95% confidence interval [CI], 0.36 to 0.69) and in the intention-to-treat group (median, 10.2 months and 6.4 months, respectively; hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001 for both comparisons). In an exploratory analysis in the ATM subgroup, the median duration of imaging-based progression-free survival was 8.1 months in the rucaparib group and 6.8 months in the control group (hazard ratio, 0.95; 95% CI, 0.59 to 1.52). The most frequent adverse events with rucaparib were fatigue and nausea. CONCLUSIONS: alteration. (Funded by Clovis Oncology; TRITON3 ClinicalTrials.gov number, NCT02975934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 3 randomized trials PROfound (NCT02987543), and TRITON-3 (NCT02975934), treatment with PARP inhibitors was favored in both chemotherapy-naïve patients and those who had received prior taxane-based chemotherapy [57, 58].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an exploratory analysis of a subgroup of TRITON-3 evaluating patients with BRCA alterations, the median PFS with rucaparib (11.2 months) was longer than with docetaxel (6.4 months; p < 0.001) [57].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Self-citationAshworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Research works printed but not linked: 2
- Rubraca (rucaparib) tablets. Boulder, CO: Clovis Oncology, 2022 (package insert).
- Lynparza (olaparib) tablets. Wilmington, DE: AstraZeneca Pharmaceuticals, 2022 (package insert).
Cited by
Sorted by citations
Items 101–200 of 452
Slootbeek, P. H. J., Kloots, I. S. H., van Oort, I. M., Kroeze, L. I., Schalken, J. A., Bloemendal, H. J., & Mehra, N. (2023) · Cancers · doi:10.3390/cancers15102814 · Cited by 13
The emerging role of PARP inhibitors in prostate cancer: A narrative review
Lobianco, L., Calvanese, G., D'Ausilio, D., Rossetti, S., Cecere, S. C., Ventriglia, J., Pisano, C., Tambaro, R., Napoli, M. D., Passarelli, A. M., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103000 · Cited by 14
Huang, J., Ojo, A. S., Tsao, S., Horowitz, A., Kyprianou, N., & Tsao, C. (2025) · Cancers · doi:10.3390/cancers17213441 · Cited by 13
ADP-ribosylation: An emerging direction for disease treatment
Liu, Y., Che, Y., Qiu, H.-L., Xia, H., Feng, Y.-Z., Deng, J.-Y., Yuan, Y., & Tang, Q. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102176 · Cited by 13
Xiong, X., Zhang, S., Zheng, W., Liao, X., Yang, J., Xu, H., Hu, S., Wei, Q., & Yang, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104286 · Cited by 12
Rahman, M., Akter, K., Ahmed, K. R., Fahim, M. M. H., Aktary, N., Park, M. N., Shin, S., & Kim, B. (2024) · Cancers · doi:10.3390/cancers16162777 · Cited by 16
Abida, W. M., Beltran, H., & Raychaudhuri, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473636 · Cited by 16
Self-citationPersonalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors
Maiorano, B. A., Conteduca, V., Catalano, M., Antonuzzo, L., Maiello, E., Giorgi, U. D., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104157 · Cited by 13
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Slootbeek, P. H. J., Tolmeijer, S. H., Mehra, N., & Schalken, J. A. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2266482 · Cited by 12
Smith, E. A., Belote, R. L., Cruz, N. M., Moustafa, T. E., Becker, C. A., Jiang, A., Alizada, S., Prokofyeva, A., Chan, T. Y., Seasor, T. A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03234-1 · Cited by 11
Poon, D. M. C., Cheung, W. S. K., Chiu, P. K., Chung, D. H. S., Kung, J. B. T., Lam, D. C. M., Leung, A. K., Ng, A. C. F., O’Sullivan, J. M., Teoh, J. Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530580 · Cited by 11
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Turco, F., Gillessen, S., Herrmann, K., Paone, G., & Omlin, A. G. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267730 · Cited by 11
Mulliqi, N., Blilie, A., Ji, X., Szolnoky, K., Olsson, H., Titus, M., Gonzalez, G. M., Boman, S. E., Valkonen, M., Gudlaugsson, E. G., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-097591 · Cited by 12
Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology
Fatima, Y., Jobre, K. N., Gómez‐Gómez, E., Małkiewicz, B., Vlahou, A., Mokou, M., Mischak, H., Frantzi, M., & Jankowski, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157475 · Cited by 11
Targeting genomic instability in cancer
Yap, T. A., Manning, H. C., Sapra, P., Mills, G. B., & O’Connor, M. J. (2026) · Cell · doi:10.1016/j.cell.2026.03.035 · Cited by 12
The Role of Extracellular Vesicles in the Treatment of Prostate Cancer
Hu, C., Chen, Q., Wu, T., Du, X., Dong, Y., Peng, Z., Xue, W., Sunkara, V., Cho, Y., & Dong, L. (2024) · Small · doi:10.1002/smll.202311071 · Cited by 11
Fenton, S. E., VanderWeeler, D. J., Rebbeck, T. R., & Chen, D. L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433138 · Cited by 12
PARP inhibitors alone or in combination for prostate cancer
de la Maza, M. D. F., Perez‐Gracia, J. L., López, B. M., & Castro, E. (2024) · Therapeutic Advances in Urology · doi:10.1177/17562872241272929 · Cited by 12
PROTAC as a novel anti-cancer strategy by targeting aging-related signaling
Peng, Y., Liu, D., Huang, D., Inuzuka, H., & Liu, J. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.004 · Cited by 10
Fracassi, G., Lorenzin, F., Orlando, F., Gioia, U., D’Amato, G., Casaramona, A. S., Cantore, T., Prandi, D., Santer, F. R., Klocker, H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179393 · Cited by 11
Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer
Hofstad, M. E., Woods, A., Parra, K., Sychev, Z. E., Mazzagatti, A., Huo, X., Yu, L., Gilbreath, C., Chen, W., Davis, A. J., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03343-x · Cited by 10
Gales, L. N., Păun, M.-A., Butnariu, I., Simion, L., Manolescu, L. S. C., Trifanescu, O. G., & Anghel, R. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073123 · Cited by 12
Fred Saad, C., Armstrong, A. J., Shore, N. D., George, D. J., Oya, M., Sugimoto, M., McKay, R. R., Hussain, M., & Clarke, N. W. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01146-4 · Cited by 15
Xu, J., Lu, J. Z., Gielzak, M., Zheng, S. L., Lu, L., Wei, J., Cornell, B., Shi, Z., Wang, Q., Tran, H., et al. (2025) · The Prostate · doi:10.1002/pros.24918 · Cited by 10
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy
Nouruzi, S., Kobelev, M., Tabrizian, N., Gleave, M. E., & Zoubeidi, A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00282-8 · Cited by 13
Xiang, J., Li, J., Guo, Z., Wu, J., Ma, D., Xu, H., Shang, T., Pu, P., Cong, L., Zhou, R., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00908-0 · Cited by 11
Tumor heterogeneity: development, mechanisms, and therapeutic implications
Zhang, J., Li, H., Ru, S., Feng, H., Guo, J., Sun, D., Xiang, T., Xu, D., & Luo, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02749-7 · Cited by 12
Slootbeek, P. H. J., Overbeek, J. K., Ligtenberg, M. J. L., van Erp, N. P., & Mehra, N. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216367 · Cited by 10
Cimadamore, A., Rescigno, P., Conteduca, V., Caliò, A., Allegritti, M., Calò, V., Montagnani, I., Lucianò, R., Patruno, M., Sergio Bracarda, A., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03660-0 · Cited by 10
Alonso‐Gordoa, T., Goodman, M. M., Vulsteke, C., Roubaud, G., Zhang, J., Parikh, M., Piulats, J. M., Azaro, A., James, G. D., Cavazzina, R., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103446 · Cited by 10
Self-citationPoly (ADP-ribose) polymerase inhibitors in cancer therapy
Zhu, Z., & Shi, Y. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003471 · Cited by 10
Targeting base excision repair in precision oncology
Montaldo, N. P., Nilsen, H. L., & Bordin, D. L. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103844 · Cited by 10
Alameddine, Z., Niazi, M. R. K., Rajavel, A., Behgal, J., Keesari, P. R., Araji, G., Mustafa, A., Wei, C., Jahangir, A., & Terjanian, T. O. (2023) · Current Oncology · doi:10.3390/curroncol30100669 · Cited by 9
Graham, L. S., Henderson, N., Kellezi, O., Hwang, C., Barata, P. C., Bilen, M. A., Kilari, D., Pierro, M. J., Thapa, B., Tripathi, A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00014 · Cited by 9
Zacchi, F., Abida, W. M., Antonarakis, E. S., Bryce, A. H., Castro, E., Cheng, H. H., Shandhu, S., & Mateo, J. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.11.011 · Cited by 9
Self-citationCalabrese, M., Saporita, I., Turco, F., Gillessen, S., Castro, E., Vogl, U. M., Stefano, R. F. D., Carfì, F. M., Poletto, S., Farinea, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010078 · Cited by 9
Blood-based liquid biopsy in advanced prostate cancer
Giunta, E. F., Malapelle, U., Russo, A. D., & Giorgi, U. D. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104241 · Cited by 9
Broomfield, J., Kalofonou, M., Bevan, C. L., & Georgiou, P. (2024) · Biosensors · doi:10.3390/bios14090443 · Cited by 8
Saeed, F., Berchuck, J. E., Bilen, M. A., Gandhi, J. S., Nazha, B., Brown, J. T., Schuster, D. M., Jani, A. B., Yu, J., & Harik, L. R. (2025) · Cancer · doi:10.1002/cncr.70037 · Cited by 9
The interconnection between androgen receptor and DNA damage response pathways in prostate cancer
Sands, M., Adams, S. B., Lee, J., Li, M., Wang, M., Walsh, T., Leon, L., Zablah, A., Haerens, M., Liu, Z., et al. (2025) · Current Urology · doi:10.1097/cu9.0000000000000300 · Cited by 11
Yu, E.-M., Hwang, M. W., & Aragon‐Ching, J. B. (2023) · Research and Reports in Urology · doi:10.2147/rru.s386517 · Cited by 8
Lu, B., Liu, Y., Yao, Y., Yang, T., Zhang, H., Yang, X., Huang, R., Wang, Z., Pan, X., & Cui, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1355551 · Cited by 8
Zhu, Q., Chen, J., Liu, H., Zhao, J., Xu, C., Sun, G., & Zeng, H. (2024) · BMC Cancer · doi:10.1186/s12885-024-12388-2 · Cited by 8
Santis, M. D., Breijo, S. M., Robinson, P. J., Capone, C., Pascoe, K. C., Sanden, S. V., Hashim, M., Trevisan, M., Daly, C., Reitsma, F., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02918-6 · Cited by 8
Ingrosso, G., Lancia, A., Bardoscia, L., Becherini, C., Bottero, M., Bertini, N., Cai, T., Caini, S., Caserta, C., Doccioli, C., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2509760 · Cited by 8
The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies
Maughan, B. L., Dyrskjøt, L., Grivas, P. D., Alcaraz, A., Antonarakis, E. S., Bilen, M. A., Bivalacqua, T. J., Cooperberg, M. R., Liang Cheng, C., & Gupta, S. (2025) · European Urology · doi:10.1016/j.eururo.2025.07.016 · Cited by 9
Batra, A., Glick, D., & Valdes, M. (2024) · Current Oncology · doi:10.3390/curroncol31020078 · Cited by 9
Sahu, K. K., Li, H., Thomas, V. M., Benson, M., Boucher, K. M., Gupta, S. V., Kohli, M., Swami, U., Agarwal, N., & Maughan, B. L. (2024) · The Oncologist · doi:10.1093/oncolo/oyae030 · Cited by 8
Precision medicine for prostate cancer: An international perspective
Hamid, A., Sweeney, C. J., Hovens, C. M., Corcoran, N. M., & Azad, A. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.02.004 · Cited by 9
Maiorano, B. A., Catalano, M., Mercinelli, C., Cigliola, A., Tateo, V., Agarwal, N., Gupta, S., Roviello, G., & Necchi, A. (2025) · European Urology Open Science · doi:10.1016/j.euros.2024.12.008 · Cited by 7
Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
Meagher, M. F., Salmasi, A., & Stewart, T. F. (2023) · Research and Reports in Urology · doi:10.2147/rru.s398129 · Cited by 7
Paller, C. J., Barata, P. C., Lorentz, J., Appleman, L. J., Armstrong, A. J., DeMarco, T. A., Dreicer, R., Elrod, J. A., Fleming, M. T., George, C., et al. (2023) · The Prostate · doi:10.1002/pros.24650 · Cited by 7
Viscuse, P. V., Devitt, M. E., & Dreicer, R. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267006 · Cited by 7
Yazgan, S. C., Akkuş, E., Yekedüz, E., & Urun, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104376 · Cited by 7
Kopp, R. M., Aláez‐Verson, C., Angel, M. O., Delgado, A., Velho, P. I., Manduley, A., Tejado-Gallegos, L. F., Rodríguez, Y., Vargas, C., & Barata, P. C. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00628 · Cited by 7
Baboudjian, M., Peyrottes, A., Dariane, C., Fromont, G., Denis, J. A., Fiard, G., Kassab, D., Ladoire, S., Lehmann‐Che, J., Ploussard, G., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.05.003 · Cited by 7
Ceci, F., Farulla, L. S. A., Bonatto, E., Evangelista, L., Aliprandi, M., Cecchi, L. G., Mattana, F., Bertocchi, A., Vincenzo, F. D., Perrino, M., et al. (2024) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.24.03575-1 · Cited by 7
Roberto, M., Civita, M. A. D., Marinelli, D., Torchia, A., Cara, N., Maltese, G., Speranza, I., & Santini, D. (2025) · BJUI Compass · doi:10.1002/bco2.455 · Cited by 7
Raychaudhuri, R., Tuchayi, A. M., Low, S. K., Arafa, A. T., Graham, L. S., Gulati, R., Pritchard, C. C., Montgomery, B., Haffner, M. C., Nelson, P. S., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.01.002 · Cited by 7
Zhao, J., Tang, B., Shen, P., Zeng, H., & Wei, Q. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104698 · Cited by 7
Kazmi, F., Shrestha, N., Liu, T. F. D., Foord, T. H., Heesen, P., Booth, S. W., Dodwell, D. J., Lord, S., Yeoh, K., & Blagden, S. P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014872.pub2 · Cited by 8
Molecular imaging of PARP in cancer: state-of-the-art
Filippi, L., Urso, L., Frantellizzi, V., Marzo, K., Marzola, M. C., Schillaci, O., & Evangelista, L. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2287503 · Cited by 7
BRCA and Beyond: Impact on Therapeutic Choices Across Cancer
Tan, J. S. H., Zhang, Z., Goh, H. X., & Ngeow, J. Y. Y. (2024) · Cancers · doi:10.3390/cancers17010008 · Cited by 8
Shared mechanisms for metastasis and drug resistance in prostate cancer
Chen, Y., Chen, L., Xu, Y., Cheng, H., & Zhou, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189358 · Cited by 6
Illuzzi, G., Galbiati, A., Staniszewska, A. D., Hanson, R., Michaloglou, C., Cooke, S. L., Uznańska, K., Białecka, M., Solarczyk, K. J., Dev, H., et al. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf035 · Cited by 6
Prostate cancer and genetic contributions
Chou, W. H., Chalker, C., Sokolova, A. O., & Isharwal, S. (2024) · Andrology · doi:10.1111/andr.13812 · Cited by 6
Exploring the role of pomalidomide in androgen-dependent prostate cancer: a computational analysis
Pathak, S., Singh, V. K., Gupta, P. K., Mahapatra, A. K., Giri, R., Sahu, R., Sharma, R., & Garg, N. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11081-7 · Cited by 6
Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therapy
Luo, Y., Nie, M., Chen, Y., Huang, X., Cui, X., Lin, W., Xu, L., Li, E., & Cheng, Y. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096327635241021115944 · Cited by 6
Fu, S., Zou, P., Fang, Z., Zhou, X., Chen, J., Gong, C., Li, Q., Lin, B., Qiu, C., Lang, J., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13579-1 · Cited by 6
Wang, C., Han, X., Kong, S., Zhang, S., Ning, H., & Wu, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117955 · Cited by 7
PARP inhibitors in prostate cancers, is it time for combinations?
Teyssonneau, D., Dariane, C., Barret, É., Beauval, J., Brureau, L., Fiard, G., Fromont, G., Créhange, G., Gauthé, M., Ruffion, A., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241242959 · Cited by 6
Bilen, M. A., Burbage, S. C., Rossi, C., Khilfeh, I., Diaz, L., Wang, Y., Pilon, D., Brown, G. A., Shore, N. D., Lowentritt, B. H., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03270-z · Cited by 5
Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer
Raychaudhuri, R., Garraway, I. P., Maxwell, K. N., Rettig, M., Desai, H., Schoen, M. W., Schweizer, M. T., Beltran, H., Nelson, P. S., & Montgomery, B. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00341 · Cited by 5
Mehr, S., & Hauke, R. J. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00377-9 · Cited by 5
Baghdadi, T. A., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Crysler, O., Mileham, K. F., Farrington, L. C., Adesunloye, B. A., Dublis, S. A., Astsaturov, I. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00649 · Cited by 5
Incorvaia, L., Puglisi, M., Maruzzo, M., Mammone, G., Caffo, O., Procopio, G., Antonuzzo, L., Rizzo, M., Conteduca, V., Messina, C. G. M., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf395 · Cited by 5
Roessler, N., Miszczyk, M., Miyajima, K., Dematteis, A., Alfarhan, A. R., Cormio, A., Alqahtani, A. S., Fazekas, T., Schuettfort, V. M., Vetterlein, M. W., et al. (2025) · European Urology Focus · doi:10.1016/j.euf.2025.12.007 · Cited by 6
Zaman, N., Kushwah, A. S., Badriprasad, A., & Chakraborty, G. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.03.004 · Cited by 5
Systemic therapy landscape of advanced prostate cancer
Paul, A. K. R., Melson, J. W., Hirani, S., & Muthusamy, S. (2024) · Advances in cancer research · doi:10.1016/bs.acr.2024.04.004 · Cited by 5
Azad, A., Gurney, H., Campbell, A., Goh, J. C. H., & Rathi, V. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14150 · Cited by 6
Mammone, G., Borghesi, S., Borsellino, N., Caliò, A., Ceccarelli, R., Cimadamore, A., Conti, G. N., Cortesi, L., D’Angelillo, R. M., Facchini, G., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13521-5 · Cited by 5
Rannikko, A. S., Hölsä, O., Ågesen, T. H., Ekman, M., & Mattila, R. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.42173 · Cited by 5
Kancherla, R., Mulka, S. R., Lohith, T. N., Bhattacharjee, A., Nagarajaiah, H., Chhajed, S. S., Satyanarayana, G. V., & Reddy, M. B. M. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142806 · Cited by 5
Peng, N., Chen, D., Yang, M., Zeng, C., & Li, W. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107193 · Cited by 6
Fukushima, T., Goto, K., Hayashi, T., Ikeda, K., Hatayama, T., Yamanaka, R., Iwane, K., Tasaka, R., Kohada, Y., Takemoto, K., et al. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad148 · Cited by 5
Li, L., Li, S., Zhang, X., Mei, L., Fu, X., Dai, M., & Wei, N. (2024) · Aging · doi:10.18632/aging.205366 · Cited by 5
Leuva, H., Zhou, M., Jamaleddine, N., Meseha, M., Faiena, I., Park, Y. A., McWilliams, G. W., Luhrs, C. A., Maxwell, K. N., Hoff, D. D. V., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105288 · Cited by 5
Madan, R. A., Karzai, F. H., VanderWeele, D. J., Cheng, H. H., & Bono, J. S. D. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01502 · Cited by 5
Zheng, C., Wang, Z., Li, L., Jiang, Y., Tang, Y., Wang, Y., Hao, X., Zhang, C., Guo, X., Yu, W., et al. (2023) · Medicina · doi:10.3390/medicina59122198 · Cited by 4
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer
Guida, A., Mosillo, C., Mammone, G., Caserta, C., Sirgiovanni, G., Conteduca, V., & Sergio Bracarda, A. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102766 · Cited by 4
Viscuse, P. V., Skelton, W. P., Devitt, M. E., & Dreicer, R. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00591 · Cited by 4
Ploussard, G., Dariane, C., Mathiéu, R., Baboudjian, M., Barret, É., Brureau, L., Fiard, G., Fromont, G., Olivier, J., Rozet, F., et al. (2024) · The French Journal of Urology · doi:10.1016/j.fjurol.2024.102710 · Cited by 5
Wang, Q., Li, Z., Jiang, Y., Feng, J., Ruan, Q. Z., Yin, G., Han, P., & Zhang, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108063 · Cited by 4
Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects
dos Reis, A. F. P., Faulkner, L. G., Lai, I. W., Dev, H., & Pacey, S. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103804 · Cited by 4
Raychaudhuri, R., Cheng, H. H., Gulati, R., Schweizer, M. T., Lin, A., Yezefski, T., Khan, H. M., Yu, E. Y., Hawley, J. E., Nelson, P. S., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.04.026 · Cited by 4
Wosny, M., Aeppli, S., Fischer, S., Peres, T., Rothermundt, C. A., & Hastings, J. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01148-2 · Cited by 4
Aldea, M. D., Orillard, É., Bernard‐Tessier, A., Cerbone, L., Pérez, C. L., Koster, K., Roubaud, G., Giorgi, U. D., Joly, F., Cherifi, F., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00310 · Cited by 4
Self-citationTani, M., Hatano, K., Ishizuya, Y., Oka, T., Kanaki, T., Inoguchi, S., Yoshimura, A., Horibe, Y., Liu, Y., Nesrine, S., et al. (2025) · Cancer Science · doi:10.1111/cas.70194 · Cited by 5
Kazmi, F., Katyal, R., Liu, T. F. D., Gkogkou, P., Blagden, S. P., Lord, S., Dodwell, D. J., & Shrestha, N. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103943 · Cited by 5
del Alba, A. G., Ballesteros, C. M., Arranz, J. Á., Gallardo, E., Sarrió, R. G., López‐Campos, F., Rodríguez, J. M., Méndez-Vidal, M. J., & Iturriaga, A. G. (2025) · Cancers · doi:10.3390/cancers17193208 · Cited by 4
Metadata
- Authors
- Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., Lindberg, H., Morris, D., Nolè, F., Staffurth, J., Redfern, C., Sáez, M. I., Abida, W., Daugaard, G., Heidenreich, A., Krieger, L., Sautois, B., Loehr, A., Despain, D., Heyes, C. A., Watkins, S. P., Chowdhury, S., Ryan, C. J., & Bryce, A. H.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Guy's Hospital (GB)
- University of Minnesota (US)
- ORCID
- Fizazi, Karim
- Piulats, Josep M.
- Reaume, M. Neil
- Ostler, Peter
- McDermott, Ray
- Gingerich, Joel R.
- Pintus, Elias
- Sridhar, Srikala S.
- Bambury, Richard M.
- Emmenegger, Urban
- Lindberg, Henriette
- Morris, David
- Nolè, Franco
- Staffurth, John
- Abida, Wassim
- Daugaard, Gedske
- Heidenreich, Axel
- Krieger, Laurence
- Sautois, Brieuc
- Loehr, Andrea
- Despain, Darrin
- Watkins, Simon P.
- Ryan, Charles J.
- Bryce, Alan H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-02-23
- Volume
- 388
- Issue
- 8
- Pages
- 719-732
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10064172
- OpenAlex
- W4321079951
- Cited by
- 449
- References
- 27
- Citations by year
- 2026: 91 · 2025: 134 · 2024: 139 · 2023: 85
- FWCI
- 82.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- Funders
- Clovis Oncology
- National Cancer Institute (P30-CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- rucaparib, metastatic prostate cancer, PARP inhibitors, BRCA mutations, ATM mutations, progression-free survival, androgen receptor pathway inhibitors, docetaxel, abiraterone, enzalutamide, PARP inhibitor resistance
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Docetaxel, Progression-Free Survival, Androgen Antagonists, Androstenes, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Indoles, Male, Nitriles, Phenylthiohydantoin, Disease Progression, Genes, BRCA1, Genes, BRCA2, Ataxia Telangiectasia Mutated Proteins, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
